Clinical Trial Update: Phase II Study of Niraparib in Metastatic TNBC Patients With Homologous Recombination Deficiency [Phase 2]

View source ↗

Summary

Phase II trial update for niraparib in metastatic triple negative breast cancer with homologous recombination deficiency.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Triple-negative Breast Cancer

Drugs mentioned

• Niraparib (Niraparib)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Homologous Recombination Deficiency, Triple Negative Breast Cancer | Phase 2 | Status: UNKNOWN